Promising early data on Sanofi's amcenestrant presented at ASCO

7 June 2021

French pharma major Sanofi (Euronext: SAN) presented new data for its oral selective estrogen receptor degrader (SERD), amcenestrant, in combination with Ibrance (CDK4/6 inhibitor), at this year’s meeting of the American Society for Clinical Oncology (ASCO).

Peter Adamson, Sanofi’s global head of oncology, clinical development and pediatric innovation, said the interim data from the Phase I AMEERA-1 study is promising, given the unmet medical need in ER+ breast cancer. Mr Adamson said seven in 10 women will have breast cancer that is hormone receptor positive. Of those, 30% will become metastatic with a median survival of five years.

Planning Phase III trial

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK